UY35908A - Moduladores de tetrahidropiridopirazinas de gpr6 - Google Patents

Moduladores de tetrahidropiridopirazinas de gpr6

Info

Publication number
UY35908A
UY35908A UY0001035908A UY35908A UY35908A UY 35908 A UY35908 A UY 35908A UY 0001035908 A UY0001035908 A UY 0001035908A UY 35908 A UY35908 A UY 35908A UY 35908 A UY35908 A UY 35908A
Authority
UY
Uruguay
Prior art keywords
gpr6
modulators
tetrahydropiridopirazin
compounds
intermediates
Prior art date
Application number
UY0001035908A
Other languages
English (en)
Inventor
Brown Jason
Hitchcock Stephen
Hopkins Maria
Monenschein Holger
Reichard Holly
Sun Huikai
Macklin Todd
Kikuchi Shota
Schleicher Kristein
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52440811&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35908A publication Critical patent/UY35908A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos de fórmula I:que son útiles como moduladores de GPR6, sus composiciones farmacéuticas, los métodos para el tratamiento de afecciones asociadas con GPR6, los procesos para realizar los compuestos y sus intermediarios.
UY0001035908A 2013-12-20 2014-12-19 Moduladores de tetrahidropiridopirazinas de gpr6 UY35908A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361919661P 2013-12-20 2013-12-20

Publications (1)

Publication Number Publication Date
UY35908A true UY35908A (es) 2015-07-31

Family

ID=52440811

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035908A UY35908A (es) 2013-12-20 2014-12-19 Moduladores de tetrahidropiridopirazinas de gpr6

Country Status (41)

Country Link
US (4) US9181249B2 (es)
EP (2) EP3083620B1 (es)
JP (1) JP6538697B2 (es)
KR (1) KR102441531B1 (es)
CN (2) CN108658978A (es)
AR (1) AR098872A1 (es)
AU (1) AU2014368992C1 (es)
BR (1) BR112016014020B1 (es)
CA (1) CA2934247C (es)
CL (1) CL2016001595A1 (es)
CR (1) CR20160321A (es)
CY (1) CY1121395T1 (es)
DK (1) DK3083620T3 (es)
DO (1) DOP2016000144A (es)
EA (1) EA032443B1 (es)
EC (1) ECSP16061758A (es)
ES (1) ES2702187T3 (es)
GE (1) GEP201706783B (es)
HR (1) HRP20182004T1 (es)
HU (1) HUE042443T2 (es)
IL (1) IL246177B (es)
JO (1) JO3466B1 (es)
LT (1) LT3083620T (es)
MA (1) MA39193B1 (es)
MX (1) MX2016008188A (es)
MY (1) MY177031A (es)
NZ (1) NZ721723A (es)
PE (1) PE20160751A1 (es)
PH (1) PH12016501192B1 (es)
PL (1) PL3083620T3 (es)
PT (1) PT3083620T (es)
RS (1) RS58092B1 (es)
SG (1) SG11201604921TA (es)
SI (1) SI3083620T1 (es)
TN (1) TN2016000244A1 (es)
TR (1) TR201900038T4 (es)
TW (2) TWI730937B (es)
UA (1) UA120427C2 (es)
UY (1) UY35908A (es)
WO (1) WO2015095728A1 (es)
ZA (1) ZA201604703B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622578B (zh) 2011-12-21 2018-05-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EA035500B1 (ru) 2013-05-17 2020-06-25 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
CN105980378B (zh) 2014-02-06 2019-09-27 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2015123505A1 (en) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005302A1 (en) * 1994-08-11 1996-02-22 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
JP2004515449A (ja) * 1999-02-26 2004-05-27 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 第６ｇタンパク質共役型受容体の小分子調節物質
WO2001070269A1 (fr) 2000-03-24 2001-09-27 Akzo Nobel N.V. Inhibiteurs de la croissance des keratinocytes et derives d'acide hydroxamique
AU2003274005A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2004069162A2 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
ATE513831T1 (de) * 2006-04-21 2011-07-15 Pfizer Prod Inc Pyridinä3,4-büpyrazinone
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
EP2153581B1 (en) 2007-06-05 2013-07-31 Astrium Limited Remote testing system and method
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB2449929A (en) 2007-06-08 2008-12-10 Snell & Wilcox Ltd Hierarchical spatial resolution building processes to fill holes in an interpolated image
TR201910781T4 (tr) 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
US9951088B2 (en) 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
FR2995937B1 (fr) 2012-09-21 2014-09-26 Exoes Ensemble de production d'electricite a moteur a pression de vapeur
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Also Published As

Publication number Publication date
MY177031A (en) 2020-09-02
AU2014368992B2 (en) 2018-09-13
KR20160099705A (ko) 2016-08-22
SI3083620T1 (sl) 2019-02-28
TW202202497A (zh) 2022-01-16
US20160031881A1 (en) 2016-02-04
MX2016008188A (es) 2016-09-29
AU2014368992C1 (en) 2019-02-21
PH12016501192A1 (en) 2016-08-15
CN105829309A (zh) 2016-08-03
CR20160321A (es) 2016-09-28
GEP201706783B (en) 2017-11-27
CA2934247A1 (en) 2015-06-25
HUE042443T2 (hu) 2019-06-28
TWI809395B (zh) 2023-07-21
NZ721723A (en) 2021-07-30
LT3083620T (lt) 2019-02-11
PL3083620T4 (pl) 2019-09-30
JO3466B1 (ar) 2020-07-05
CN108658978A (zh) 2018-10-16
EP3083620B1 (en) 2018-10-03
CN105829309B (zh) 2018-05-15
PT3083620T (pt) 2019-01-17
MA39193B1 (fr) 2018-04-30
JP2017502027A (ja) 2017-01-19
CY1121395T1 (el) 2020-05-29
BR112016014020B1 (pt) 2023-02-28
PH12016501192B1 (en) 2016-08-15
DOP2016000144A (es) 2016-08-15
BR112016014020A8 (pt) 2018-01-30
SG11201604921TA (en) 2016-07-28
PL3083620T3 (pl) 2019-09-30
TW201605854A (zh) 2016-02-16
US9708313B2 (en) 2017-07-18
ES2702187T3 (es) 2019-02-27
DK3083620T3 (en) 2019-01-14
US20180346464A1 (en) 2018-12-06
US9181249B2 (en) 2015-11-10
JP6538697B2 (ja) 2019-07-03
HRP20182004T1 (hr) 2019-02-08
EA201691272A1 (ru) 2017-05-31
CA2934247C (en) 2023-01-17
TR201900038T4 (tr) 2019-01-21
US20150175602A1 (en) 2015-06-25
EA032443B1 (ru) 2019-05-31
RS58092B1 (sr) 2019-02-28
PE20160751A1 (es) 2016-08-01
AU2014368992A1 (en) 2016-07-07
TN2016000244A1 (en) 2017-10-06
EP3453709A1 (en) 2019-03-13
KR102441531B1 (ko) 2022-09-07
CL2016001595A1 (es) 2017-01-13
MA39193A1 (fr) 2017-06-30
ECSP16061758A (es) 2018-02-28
BR112016014020A2 (pt) 2017-08-08
AR098872A1 (es) 2016-06-22
EP3083620A1 (en) 2016-10-26
TWI730937B (zh) 2021-06-21
WO2015095728A1 (en) 2015-06-25
US10077266B2 (en) 2018-09-18
IL246177A0 (en) 2016-08-02
US10738046B2 (en) 2020-08-11
UA120427C2 (uk) 2019-12-10
US20170283414A1 (en) 2017-10-05
IL246177B (en) 2019-11-28
ZA201604703B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112016028773A2 (pt) processos para preparação de compostos antivirais
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY36204A (es) Derivados de insoindolina.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
UY36221A (es) Derivados de isoindolinona

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211221

109 Application deemed to be withdrawn

Effective date: 20221107